Emerald Bioscience Provides Update on Recent Progress and Expected 2020 Milestones
13 janv. 2020 08h30 HE
|
Emerald Bioscience, Inc.
Company prepares to enter the clinic in 2020 to test NB1111 (THCVHS) in glaucoma Preclinical formulation testing proprietary analog of CBD examining the utility of CBDVHS in the eye, brain, and...
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
18 mars 2019 07h30 HE
|
Nemus Bioscience, Inc.
Prodrug of THC Outperformed Latanoprost at Multiple Timepoints in Multiple Dosing Study NB1111 Formulation Extends Pharmaceutical Activity Time to Support Once-Daily to Twice-Daily Topical Dosing ...
Nemus Bioscience to Present at BIO Investor Forum
15 oct. 2018 08h30 HE
|
Nemus Bioscience, Inc.
LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
Nemus Bioscience Announces that Emerald Health Sciences has Provided a Credit Facility of up to $20 Million and Adopted an Open Market Share Purchase Program of up to 10 Million Common Shares
08 oct. 2018 08h00 HE
|
Nemus Bioscience, Inc.
Avtar Dhillon, MD, appointed as Executive Chairman of Nemus LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the...
NEMUS Bioscience to Participate in Sachs BioCapital USA Forum at the New York Academy of Sciences
07 mars 2018 08h30 HE
|
Nemus Bioscience, Inc.
COSTA MESA, CA., March 07, 2018 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications,...